The effects of glycogen synthase kinase-3beta in serotonin neurons

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Zhou, Wenjun ^a   Chen, Ligong ^a   Paul, Jodi ^a   Yang, Sufen ^a   Li, Fuzeng ^a   Sampson, Karen ^b   Woodgett, Jim R ^c   Beaulieu, Jean Martin ^b   Gamble, Karen L ^a   Li, Xiaohua ^a,d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITÉ LAVAL   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d Behavior Health of St Vincent East   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 HYDROXYTRYPTAMINE RECEPTOR 1B; ANPIRTOLINE; CYCLIC AMP; GLYCOGEN SYNTHASE KINASE 3BETA; SEROTONIN; SEROTONIN RECEPTOR; TRYPTOPHAN HYDROXYLASE 2; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; CROSS BREEDING; ENZYME ACTIVITY; FEMALE; KNOCKOUT MOUSE; MOUSE; NERVE CELL MEMBRANE POTENTIAL; NERVE CELL STIMULATION; NEUROMODULATION; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEROTONIN RELEASE; SEROTONINERGIC NERVE CELL;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIC AMP; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOGEN SYNTHASE KINASE 3; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; PIPERIDINES; PYRIDINES; RAPHE NUCLEI; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONERGIC NEURONS; SEROTONIN; SEROTONIN 5-HT1 RECEPTOR AGONISTS;

EID: 84865078148     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043262     Document Type: Article

References (67)

1. Embi N, Rylatt DB, Cohen P, (1980) Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107: 519-527.
2. Yao HB, Shaw PC, Wong CC, Wan DC, (2002) Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain. J Chem Neuroanat 23: 291-297.
3. Jope RS, Johnson GVW, (2004) The glamour and gloom of glycogen synthase kinase-3. Trehds in Biochemical Sci 29: 95-102.
4. Pap M, Cooper GM, (1998) Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 273: 19929-19932.
5. Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, et al. (2004) In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 29: 1426-1431.
6. Mai L, Jope RS, Li X, (2002) BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J Neurochem 82: 75-83.
7. Johnson-Farley NN, Travkina T, Cowen DS, (2006) Cumulative activation of akt and consequent inhibition of glycogen synthase kinase-3 by brain-derived neurotrophic factor and insulin-like growth factor-1 in cultured hippocampal neurons. J Pharmacol Exp Ther 316: 1062-1069.
8. Polter AM, Li X (2011) Glycogen synthase kinase-3 is an intermediate modulator of serotonin neurotransmission. Front Mol Neurosci 4.
9. Klein PS, Melton DA, (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93: 8455-8459.
10. Stambolic V, Ruel L, Woodgett JR, (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6: 1664-1668.
11. Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, et al. (2008) Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci U S A 105: 1333-1338.
12. Alimohamad H, Rajakumar N, Seah YH, Rushlow W, (2005) Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 57: 533-542.
13. Li X, Rosborough KM, Friedman AB, Zhu W, Roth KA, (2007) Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int J Neuropsychopharmacol 10: 7-19.
14. Roh MS, Seo MS, Kim Y, Kim SH, Jeon WJ, et al. (2007) Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex. Exp Mol Med 39: 353-360.
15. Woodgett JR, (2001) Judging a protein by more than its name: GSK-3. Sci STKE 2001: RE12.
16. Woodgett JR, (1990) Molecular cloning and expression of glycogen synthase kinase-3/factor A. Embo J. 9: 2431-2438.
17. Liang MH, Chuang DM, (2007) Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J Biol Chem 282: 3904-3917.
18. Liang MH, Chuang DM, (2006) Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. J Biol Chem 281: 30479-30484.
19. Wang QM, Park IK, Fiol CJ, Roach PJ, DePaoli-Roach AA, (1994) Isoform differences in substrate recognition by glycogen synthase kinases 3 alpha and 3 beta in the phosphorylation of phosphatase inhibitor 2. Biochemistry 33: 143-147.
20. Phiel CJ, Wilson CA, Lee VM, Klein PS, (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423: 435-439.
21. Chen L, Zhou W, Chen P, Gaisina I, Yang S, et al. (2011) Glycogen Synthase Kinase-3beta is a Functional Modulator of Serotonin 1B Receptors. Mol Pharmacol 79: 974-986.
22. Chen L, Salinas GD, Li X, (2009) Regulation of serotonin 1B receptor by glycogen synthase kinase-3. Mol Pharmacol 76: 1150-1161.
23. Doble BW, Woodgett JR, (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175-1186.
24. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG, (2004) Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 27: 107-144.
25. Trillat AC, Malagie I, Scearce K, Pons D, Anmella MC, et al. (1997) Regulation of serotonin release in the frontal cortex and ventral hippocampus of homozygous mice lacking 5-HT1B receptors: in vivo microdialysis studies. J Neurochem 69: 2019-2025.
26. Sari Y, (2004) Serotonin1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev 28: 565-582.
27. Riad M, Garcia S, Watkins KC, Jodoin N, Doucet E, et al. (2000) Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J Comp Neurol 417: 181-194.
28. Hoyer D, Martin G, (1997) 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 36: 419-428.
29. Bockaert J, Claeysen S, Becamel C, Dumuis A, Marin P, (2006) Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res 326: 553-572.
30. Bouhelal R, Smounya L, Bockaert J, (1988) 5-HT1B receptors are negatively coupled with adenylate cyclase in rat substantia nigra. Eur J Pharmacol 151: 189-196.
31. Leone AM, Errico M, Lin SL, Cowen DS, (2000) Activation of extracellular signal-regulated kinase (ERK) and Akt by human serotonin 5-HT(1B) receptors in transfected BE(2)-C neuroblastoma cells is inhibited by RGS4. J Neurochem 75: 934-938.
32. Patel S, Doble BW, MacAulay K, Sinclair EM, Drucker DJ, et al. (2008) Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action. Mol Cell Biol 28: 6314-6328.
33. Scott MM, Wylie CJ, Lerch JK, Murphy R, Lobur K, et al. (2005) A genetic approach to access serotonin neurons for in vivo and in vitro studies. Proc Natl Acad Sci U S A 102: 16472-16477.
34. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, et al. (2000) Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406: 86-90.
35. Kearn CS (2004) Immunofluorescent mapping of cannibinoid CB1 and dopamine D2 receptors in the mouse brain. LI-COR Biosciences website (www.licor.com), available at http://biosupport.licor.com/docs/KearnPaper.pdf. Accessed 2012 July 25.
36. Thompson BJ, Jessen T, Henry LK, Field JR, Gamble KL, et al. (2011) Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter. Proc Natl Acad Sci U S A 108: 3785-3790.
37. Lundkvist GB, Kwak Y, Davis EK, Tei H, Block GD, (2005) A calcium flux is required for circadian rhythm generation in mammalian pacemaker neurons. J Neurosci 25: 7682-7686.
38. Raymond JR, Mukhin YV, Gelasco A, Turner J, Collinsworth G, et al. (2001) Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther 92: 179-212.
39. Cheetham SC, Heal DJ, (1993) Evidence that RU 24969-induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5-HT1B receptor. Br J Pharmacol 110: 1621-1629.
40. Chaouloff F, Courvoisier H, Moisan MP, Mormede P, (1999) GR 127935 reduces basal locomotor activity and prevents RU 24969-, but not D-amphetamine-induced hyperlocomotion, in the Wistar-Kyoto hyperactive (WKHA) rat. Psychopharmacology (Berl) 141: 326-331.
41. Walsh RN, Cummins RA, (1976) The Open-Field Test: a critical review. Psychol Bull 83: 482-504.
42. Chenu F, David DJ, Leroux-Nicollet I, Le Maitre E, Gardier AM, et al. (2008) Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system. J Psychiatry Neurosci 33: 541-550.
43. O'Neill MF, Fernandez AG, Palacios JM, (1996) GR 127935 blocks the locomotor and antidepressant-like effects of RU 24969 and the action of antidepressants in the mouse tail suspension test. Pharmacol Biochem Behav 53: 535-539.
44. Rao R, Patel S, Hao C, Woodgett J, Harris R, (2010) GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity. J Am Soc Nephrol 21: 428-437.
45. Hendricks T, Francis N, Fyodorov D, Deneris ES, (1999) The ETS domain factor Pet-1 is an early and precise marker of central serotonin neurons and interacts with a conserved element in serotonergic genes. J Neurosci 19: 10348-10356.
46. Hendricks TJ, Fyodorov DV, Wegman LJ, Lelutiu NB, Pehek EA, et al. (2003) Pet-1 ETS gene plays a critical role in 5-HT neuron development and is required for normal anxiety-like and aggressive behavior. Neuron 37: 233-247.
47. Li X, Jope RS, (2010) Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology 35: 2143-2154.
48. Blier P, Pineyro G, el Mansari M, Bergeron R, de Montigny C, (1998) Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann N Y Acad Sci 861: 204-216.
49. Polter AM, Yang S, Jope RS, Li X, (2012) Functional significance of glycogen synthase kinase-3 regulation by serotonin. Cell Signal 24: 265-271.
50. Ruf BM, Bhagwagar Z, (2009) The 5-HT1B receptor: a novel target for the pathophysiology of depression. Curr Drug Targets 10: 1118-1138.
51. Clark MS, Neumaier JF, (2001) The 5-HT1B receptor: behavioral implications. Psychopharmacol Bull 35: 170-185.
52. Drago A, Alboni S, Brunello N, De Ronchi D, Serretti A, (2010) HTR1B as a risk profile maker in psychiatric disorders: a review through motivation and memory. Eur J Clin Pharmacol 66: 5-27.
53. Miczek KA, Faccidomo S, De Almeida RM, Bannai M, Fish EW, et al. (2004) Escalated aggressive behavior: new pharmacotherapeutic approaches and opportunities. Ann N Y Acad Sci 1036: 336-355.
54. Pranzatelli MR, Jappay E, Snodgrass SR, (1987) Effects of 5-HT receptor subtype-selective drugs on locomotor activity and motor habituation in the DHT adult rat model. Pharmacol Biochem Behav 27: 497-504.
55. Prut L, Belzung C, (2003) The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463: 3-33.
56. Freland L, Beaulieu JM, (2012) Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci 5: 14.
57. O'Brien WT, Huang J, Buccafusca R, Garskof J, Valvezan AJ, et al. (2011) Glycogen synthase kinase-3 is essential for beta-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest 121: 3756-3762.
58. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, et al. (2008) A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132: 125-136.
59. Valvezan AJ, Klein PS, (2012) GSK-3 and Wnt Signaling in Neurogenesis and Bipolar Disorder. Front Mol Neurosci 5: 1.
60. Massot O, Rousselle JC, Fillion MP, Januel D, Plantefol M, et al. (1999) 5-HT1B receptors: a novel target for lithium. Possible involvement in mood disorders. Neuropsychopharmacology 21: 530-541.
61. Cade JF, (1949) Lithium salts in the treatment of psychotic excitement. Med J Aust 2: 349-352.
62. Rogers DC, Fisher EM, Brown SD, Peters J, Hunter AJ, et al. (1997) Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm Genome 8: 711-713.
63. Nunemaker CS, DeFazio RA, Moenter SM, (2003) A targeted extracellular approach for recording long-term firing patterns of excitable cells: a practical guide. Biol Proced Online 5: 53-62.
64. Evans AK, Reinders N, Ashford KA, Christie IN, Wakerley JB, et al. (2008) Evidence for serotonin synthesis-dependent regulation of in vitro neuronal firing rates in the midbrain raphe complex. Eur J Pharmacol 590: 136-149.
65. Jones BJ, Roberts DJ, (1968) The quantiative measurement of motor inco-ordination in naive mice using an acelerating rotarod. J Pharm Pharmacol 20: 302-304.
66. Polter AM, Beurel E, Yang S, Garner R, Song L, et al. (2010) Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 35: 1761-1774.
67. Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates: Elsevier.